Striatal dopamine nerve terminal markers in human, chronic methamphetamine users

Nature Medicine

Volumn 2, Issue 6, 1996, Pages 699-703

  Wilson, Julie M ^a   Kalasinsky, Kathryn S ^b   Levey, Allan I ^c   Bergeron, Catherine ^d   Reiber, Gregory ^e   Anthony, Robert M ^e   Schmunk, Gregory A ^f   Shannak, Kathleen ^a   Haycock, John W ^g   Kish, Stephen J ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TORONTO GENERAL HOSPITAL   (Canada)

^e N California Forensic Pathology   (United States)

^f Off of the Brown Co Med Examiner   (United States)

^g LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; METHAMPHETAMINE;

ADULT; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; DOPAMINERGIC NERVE CELL; DRUG ABUSE; DYSPHORIA; FEMALE; HUMAN; MALE; NERVE CELL DEGENERATION; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PUTAMEN;

ADULT; AUTOPSY; CARRIER PROTEINS; CHRONIC DISEASE; CORPUS STRIATUM; DOPA DECARBOXYLASE; DOPAMINE; DOPAMINE AGENTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; METHAMPHETAMINE; NERVE ENDINGS; NERVE TISSUE PROTEINS; NEUROPEPTIDES; NUCLEUS ACCUMBENS; PUTAMEN; TYROSINE 3-MONOOXYGENASE; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

PRIMATES;

EID: 15844384993     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0696-699     Document Type: Article

References (35)

1. Seiden, L.S., Fishman, M.W. & Schuster, C.R. Long-term methamphetamine-induced changes in tolerant rhesus monkeys. Drug Alcohol Depend. 1, 215-219 (1976).
2. Preston, K.L., Wagner, G.C., Schuster, C.R. & Seiden, L.S. Long-term effects of repeated methylamphetamine administration on monoamine neurons in the rhesus monkey brain. Brain Res. 338, 243-248 (1985).
3. Woolverton, W.L., Ricaurte, G.A., Forno, L.S. & Seiden, L.S. Long-term effects of chronic methamphetamine administration in rhesus monkeys. Brain Res. 486, 73-78 (1989).
4. Wilson, J.M. et al. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology (in the press).
5. Zhong, X.H. et al. Striatal tyrosine hydroxylase and dopa decarboxylase protein in dominantly-inherited olivopontocerebellar atrophy and idiopathic Parkinson's disease. Mov. Disord. 10, 10-17 (1995).
6. DiChiara, G. The role of dopamine in drug abuse reviewed from the perspective of its role in motivation. Drug Alcohol Depend. 38, 95-137 (1995).
7. Laruelle, M. et al. SPECT imaging of striatal dopamine release after amphetamine challenge. J. Nucl. Med. 36, 1182-1190 (1995).
8. Hartman, J.A. & Halaris, A.E. Compartmentation of catecholamines in rat brain: Effects of agonists and antagonists. Brain Res. 190, 421-436 (1980).
9. Kuczenski, R. Amphetamine-haloperidol interactions on striatal and mesolimbic tyrosine hydroxylase activity and dopamine metabolism. J. Pharmacol. Exp. Ther. 215, 135-142 (1980).
10. Chan, P. et al. Rapid ATP loss caused by methamphetamine in the mouse striatum: Relationship between energy impairment and dopaminergic neurotoxicity. J. Neurochem. 62, 2484-2487 (1994).
11. Ricaurte, G.A., Schuster C.R. & Seiden, L.S. Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: A regional study. Brain Res. 193, 153-163 (1980).
12. Ricaurte, G.A., Guillery, R.W., Seiden, L.S., Schuster, C.R. & Moore, R.Y. Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res. 235, 93-103 (1982).
13. Brunswick, D.J., Benmansour, S., Tejani-Butt, S.M. & Hauptmann, M. Effects of high-dose methamphetamine on monoamine uptake sites in rat brain measured by quantitative autoradiography. Synapse 11, 287-293 (1992).
14. O'Callaghan, J.P. & Miller, D.B. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Ther. 270, 741-751 (1994).
15. Miller, D.B. & O'Callaghan, J.P. Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Ther. 270, 752-760 (1994).
16. Kish, S.J., Shannak, K. & Hornykiewicz, O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N. Engl. J. Med. 318, 867-880 (1988).
17. DaSilva, J.N., Kilbourn, M.R. & Domino, E.F. In vivo imaging of monoaminergic nerve terminals in normal and MPTP-lesioned primate brain using positron emission tomography (PET). Synapse 14, 128-131 (1993).
18. Giros, B. et al. Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters. J. Biol. Chem. 269, 15985-15988 (1994).
19. Vaughan, R.A. Photoaffinity-labeled ligand binding domains on dopamine transporters identified by peptide mapping. Mol. Pharmacol. 47, 956-964 (1994).
20. 3H-GBR 12,935 are differentially regulated by chronic cocaine self-administration. J. Neurosci. 14, 2966-2979 (1994).
21. Vander Borght, T.M., Kilbourn, M.R., Desmond, T.J., Kuhl, D.E. & Frey, K.A. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur. J. Pharmacol. 294, 577-583 (1995).
22. Naudon, L., Leroux-Nicollet, I. & Costentin, J. Short-term treatments with haloperidol or bromocriptine do not alter the density of the monoamine vesicular transporter in the substantia nigra. Neurosci. Lett. 173, 1-4 (1994).
23. Wilson, J.M. & Kish, S.J. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J. Neurosci. (in the press).
24. Persico, A.M. et al. Dopaminergic gene expression during amphetamine withdrawal. NeuroReport 4, 41-44 (1993).
25. Robinson, T.E. & Berridge, K.C. The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Res. Rev. 18, 247-291 (1993).
26. Rossetti, Z.L., Hmaidan, Y. & Gessa, L. Marked inhibition of mesolimbic dopamine release: a common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats. Eur. J. Pharmacol. 221, 227-234 (1992).
27. Wise, R.A. & Munn, E. Withdrawal from chronic amphetamine elevates base-line intracranial self-administration thresholds. Psychopharmacology 117, 130-136 (1995).
28. Giros, B., Jaber, M., Jones, S.R., Wightman, R.M. & Caron, M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379, 606-612 (1996).
29. Pifl, C., Drobny, H., Reither, H., Hornykiewicz, O. & Singer, E.A. Mechanism of the dopamine-releasing actions of amphetamine and cocaine: Plasmalemmal dopamine transporter versus vesicular monoamine transporter. Mol. Pharmacol. 47, 368-373 (1995).
30. Kuikka, J.T. et al. Altered serotonin and dopamine transporter densities associated with impulse violent behaviour. J. Nucl. Med. 36, 31P-32P (1995).
31. Fishbein, D.H., Lozovsky, D. & Jaffe, J.H. Impulsivity, aggression and neuroendocrine responses to serotonergic stimulation in substance abusers. Biol. Psychiatry 25, 1049-1066 (1989).
32. Miczek, K.A. & Tidey, J.W. Amphetamines: Aggressive and social behavior. NIDA Res. Monogr. 94, 68-100 (1989).
33. Riley, H.A. An Atlas of the Basal Ganglia, Brainstem and Spinal Cord. (Hafner, New York, 1960).
34. Hörtnagl, H., Schlogl, E., Sperk, G. & Hornykiewicz, O. The topographical distribution of the monoaminergic innervation in the basal ganglia of the human brain. Prog. Brain Res. 58, 269-274 (1983).
35. Ordway, G.A., Smith, K.S. & Haycock, J.W. Elevated tyrosine hydroxylase in the locus coeruleus of suicide victims. J. Neurochem. 62, 680-685 (1994).